Cargando…
Progression of Renal Dysfunction in Patients with Cardiovascular Disease
It has been established that patients with chronic kidney disease (CKD) suffer from frequent cardiovascular events. On the other hand, recent studies suggest that renal damage tends to worsen in patients with cardiovascular diseases (CVD). Although the mechanisms for the cardiorenal association are...
Autores principales: | , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Bentham Science Publishers Ltd.
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2780821/ https://www.ncbi.nlm.nih.gov/pubmed/19936196 http://dx.doi.org/10.2174/157340308785160543 |
_version_ | 1782174529345290240 |
---|---|
author | Hirata, Yasunobu Kiyosue, Arihiro Takahashi, Masao Satonaka, Hiroshi Nagata, Daisuke Sata, Masataka Suzuki, Etsu Nagai, Ryozo |
author_facet | Hirata, Yasunobu Kiyosue, Arihiro Takahashi, Masao Satonaka, Hiroshi Nagata, Daisuke Sata, Masataka Suzuki, Etsu Nagai, Ryozo |
author_sort | Hirata, Yasunobu |
collection | PubMed |
description | It has been established that patients with chronic kidney disease (CKD) suffer from frequent cardiovascular events. On the other hand, recent studies suggest that renal damage tends to worsen in patients with cardiovascular diseases (CVD). Although the mechanisms for the cardiorenal association are unclear, the presence of arteriosclerotic risk factors common to both CVD and CKD is important. In arteriosclerosis, vascular derangement progresses not only in the heart but also in the kidney. In addition, heart failure, cardiac catheterization and hesitation of medical treatments due to renal dysfunction may explain the progression of renal damage. Therefore, the goal of treatments is a total control of arteriosclerotic risk factors. Medication should be selected among agents with protective effects on both heart and kidney. It is important to always consider the presence of CKD for the treatment of the cardiovascular disease and strictly control the risk factors. |
format | Text |
id | pubmed-2780821 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2008 |
publisher | Bentham Science Publishers Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-27808212009-11-23 Progression of Renal Dysfunction in Patients with Cardiovascular Disease Hirata, Yasunobu Kiyosue, Arihiro Takahashi, Masao Satonaka, Hiroshi Nagata, Daisuke Sata, Masataka Suzuki, Etsu Nagai, Ryozo Curr Cardiol Rev Article It has been established that patients with chronic kidney disease (CKD) suffer from frequent cardiovascular events. On the other hand, recent studies suggest that renal damage tends to worsen in patients with cardiovascular diseases (CVD). Although the mechanisms for the cardiorenal association are unclear, the presence of arteriosclerotic risk factors common to both CVD and CKD is important. In arteriosclerosis, vascular derangement progresses not only in the heart but also in the kidney. In addition, heart failure, cardiac catheterization and hesitation of medical treatments due to renal dysfunction may explain the progression of renal damage. Therefore, the goal of treatments is a total control of arteriosclerotic risk factors. Medication should be selected among agents with protective effects on both heart and kidney. It is important to always consider the presence of CKD for the treatment of the cardiovascular disease and strictly control the risk factors. Bentham Science Publishers Ltd. 2008-08 /pmc/articles/PMC2780821/ /pubmed/19936196 http://dx.doi.org/10.2174/157340308785160543 Text en ©2008 Bentham Science Publishers Ltd. http://creativecommons.org/licenses/by/2.5/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.5/) which permits unrestrictive use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Article Hirata, Yasunobu Kiyosue, Arihiro Takahashi, Masao Satonaka, Hiroshi Nagata, Daisuke Sata, Masataka Suzuki, Etsu Nagai, Ryozo Progression of Renal Dysfunction in Patients with Cardiovascular Disease |
title | Progression of Renal Dysfunction in Patients with Cardiovascular Disease |
title_full | Progression of Renal Dysfunction in Patients with Cardiovascular Disease |
title_fullStr | Progression of Renal Dysfunction in Patients with Cardiovascular Disease |
title_full_unstemmed | Progression of Renal Dysfunction in Patients with Cardiovascular Disease |
title_short | Progression of Renal Dysfunction in Patients with Cardiovascular Disease |
title_sort | progression of renal dysfunction in patients with cardiovascular disease |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2780821/ https://www.ncbi.nlm.nih.gov/pubmed/19936196 http://dx.doi.org/10.2174/157340308785160543 |
work_keys_str_mv | AT hiratayasunobu progressionofrenaldysfunctioninpatientswithcardiovasculardisease AT kiyosuearihiro progressionofrenaldysfunctioninpatientswithcardiovasculardisease AT takahashimasao progressionofrenaldysfunctioninpatientswithcardiovasculardisease AT satonakahiroshi progressionofrenaldysfunctioninpatientswithcardiovasculardisease AT nagatadaisuke progressionofrenaldysfunctioninpatientswithcardiovasculardisease AT satamasataka progressionofrenaldysfunctioninpatientswithcardiovasculardisease AT suzukietsu progressionofrenaldysfunctioninpatientswithcardiovasculardisease AT nagairyozo progressionofrenaldysfunctioninpatientswithcardiovasculardisease |